Business
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments.
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled --","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"-- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 --","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"-- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 --","length":65,"tagName":"p","attribs":{}},{"type":"text","content":"-- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 --","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"-- Strong Quarter-End Cash Position of $603 Million --","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, April 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline and other corporate developments.","length":394,"tagName":"p"},{"type":"image","alt":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Viking Therapeutics (PRNewsfoto/Viking Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZacgsMHcTH4bVMkIFotjRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/8a1e3a48ba1eed38d0965ff99386679c","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/273590/viking_9_15_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Highlights from the First Quarter Ended March 31, 2026, and Other Recent Events:","length":85,"tagName":"p"},{"type":"text","content":""We are excited to report that the advances and strong momentum Viking created in 2025 have carried forward through the first quarter of 2026," stated Brian Lian, Ph.D., chief executive officer of Viking. "Looki...